Latest Breaking News On - Prnewswire immunic inc - Page 7 : vimarsana.com

Immunic, Inc Strengthens Its Board of Directors with the Appointment of Maria Törnsén

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

Edna kaplanPaula schwartzMerck kgaDuane nashJessica breuSanofi genzymeEli lillyExchange commissionLund universityContactrx communications groupPrnewswire immunic incImmunic incGlobal commercial executive bringsMarketing expertiseJan vanBossche steps down

Immunic to Participate in Industry and Scientific Conferences in July

Immunic to Participate in Industry and Scientific Conferences in July
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalEvelyn peelenContactkogs communicationedna kaplanPrnewswire immunic incImmunic incAutoimmune disease drug development summitExchange commissionUs ir contactrx communications grouppaula schwartzScience healthImmunic inc jessica breuhead of investor relationsWorld immune regulationSenior manager translational pharmacologyOrally availableDependent autoimmunityInducing thymocyte

Immunic, Inc to Participate in Scientific, Industry and Investor Conferences in June

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

New yorkUnited statesSan diegoEdna kaplanPaula schwartzJessica breuEvelyn peelenDaniel vittSecurities life sciences conferenceInternational conventionRx communications groupPrnewswire immunic incSecurities life sciences conference onExchange commissionInternational congress on autoimmunityImmunic inc

Immunic, Inc Reports First Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

United statesNew zealandPaula schwartzEdna kaplanJessica breuGlenn whaleyDaniel vittColitis organizationRx communications groupPrnewswire immunic incExchange commissionDevelopment rd expensesEthics committeeImmunic australia pty ltdImmunic incTop line data

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

New zealandEdna kaplanPaula schwartzJessica breuDaiichi sankyoAndreas muehlerDaniel vittExchange commissionDaiichi sankyo co ltdRx communications groupPrnewswire immunic incImmunic incFirst time patients willIntestinal barrier functionBowel epitheliumChief executive officer